<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138084</url>
  </required_header>
  <id_info>
    <org_study_id>206282</org_study_id>
    <secondary_id>AI438-041</secondary_id>
    <nct_id>NCT02138084</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction (DDI) Rifabutin</brief_title>
  <official_title>Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide dosing recommendations for the coadministration of&#xD;
      BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for&#xD;
      prescribing information purposes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">July 24, 2014</completion_date>
  <primary_completion_date type="Actual">July 24, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours after dosing (C12) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-626529 (predose)</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability include incidence of adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>Up to Day 30 after discontinuation of dose (approximately 45 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: BMS-663068 tablet by mouth as specified&#xD;
Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: BMS-663068 tablet by mouth as specified&#xD;
Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin</description>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir</description>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent&#xD;
&#xD;
             a) Signed written informed consent must be obtained from the subjects in accordance&#xD;
             with requirements of the study center's Institutional Review Board (IRB) or&#xD;
             Independent Ethics Committee (IEC) before the initiation of any protocol-required&#xD;
             procedures&#xD;
&#xD;
          2. Target Population&#xD;
&#xD;
               -  a) Healthy subjects as determined by no clinically significant deviation from&#xD;
                  normal in medical history, physical examination findings, 12-lead ECG&#xD;
                  measurements, and clinical laboratory test results&#xD;
&#xD;
               -  b) Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive BMI = weight&#xD;
                  (kg)/[height (m)]2&#xD;
&#xD;
               -  c) Subject Reenrollment: This study permits the reenrollment of a subject that&#xD;
                  has discontinued the study as a pretreatment failure (ie, subject has not been&#xD;
                  randomized/has not been dosed). If reenrolled, the subject must be reconsented&#xD;
&#xD;
          3. Age and Reproductive Status&#xD;
&#xD;
               -  a) Men and women, ages 18 to 50 years, inclusive&#xD;
&#xD;
               -  b) Women of childbearing potential (WOCBP) must have a negative serum or urine&#xD;
                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human&#xD;
                  chorionic gonadotropin) within 24 hours prior to the start of study drug&#xD;
&#xD;
               -  c) Women must not be breastfeeding&#xD;
&#xD;
               -  d) WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
                  duration of treatment plus 5 half-lives of Rifabutin (13 days) plus 30 days&#xD;
                  (duration of ovulatory cycle) for a total of 43 days posttreatment completion&#xD;
&#xD;
               -  e) Men who are sexually active with WOCBP must agree to follow instructions for&#xD;
                  method(s) of contraception for the duration of treatment plus 5 half-lives of&#xD;
                  Rifabutin (13 days) plus 90 days (duration of sperm turnover) for a total of 103&#xD;
                  days posttreatment completion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical History and Concurrent Diseases&#xD;
&#xD;
          -  a) Any significant acute or chronic medical illness as determined by the Investigator.&#xD;
&#xD;
          -  b) Current or recent (within 3 months of study drug administration) gastrointestinal&#xD;
             disease&#xD;
&#xD;
          -  c) Any major surgery within 4 weeks of study drug administration&#xD;
&#xD;
          -  d) Any gastrointestinal surgery that could impact upon the absorption of study drug&#xD;
&#xD;
          -  e) Intractable diarrhea (â‰¥6 loose stools per day for at least 7 consecutive days)&#xD;
             within 30 days prior to the first dose of study drug&#xD;
&#xD;
          -  f) History of acute or chronic pancreatitis&#xD;
&#xD;
          -  g) History of active or latent tuberculosis or any recent exposure to someone with&#xD;
             tuberculosis&#xD;
&#xD;
          -  h) History of uveitis and/or current eye or vision problems with the exception of&#xD;
             corrective lenses&#xD;
&#xD;
          -  i) Contact lens use during study drug administration or the need for contact lenses&#xD;
             during study drug administration&#xD;
&#xD;
          -  j) Donation of blood to a blood bank or in a clinical study (except screening visit)&#xD;
             within 4 weeks of study drug administration (within 2 weeks for plasma donation only)&#xD;
&#xD;
          -  k) Blood transfusion within 4 weeks of study drug administration.&#xD;
&#xD;
          -  l) History of any hemolytic disorders, including drug-induced hemolysis.&#xD;
&#xD;
          -  m) Inability to tolerate oral medication&#xD;
&#xD;
          -  n) Inability to be venipunctured and/or tolerate venous access&#xD;
&#xD;
          -  o) Recent (within 6 months of study drug administration) history of smoking or current&#xD;
             smokers&#xD;
&#xD;
          -  p) Recent (within 6 months of study drug administration) drug or alcohol abuse as&#xD;
             defined in Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM&#xD;
             IV), Diagnostic Criteria for Drug and Alcohol Abuse&#xD;
&#xD;
          -  q) Any other sound medical, psychiatric, and/or social reason as determined by the&#xD;
             Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Fostemsavir</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

